^
Chr del(17p)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive
:
A2
SOHO 2022 - 6 days - (New B)
Chr del(11q)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive
:
B
SOHO 2022 - 6 days - (New B)
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
rituximab + ibrutinib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
orelabrutinib
Sensitive
:
A1
CD20 expression
Chronic Lymphocytic Leukemia
rituximab-arrx
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
Rixathon (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
rituximab-pvvr
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + rituximab
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
ibrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
ibrutinib + obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
rituximab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
ofatumumab
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
rituximab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
venetoclax
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
rituximab / hyaluronidase
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
ibrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
obinutuzumab + acalabrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
rituximab + idelalisib
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
rituximab + idelalisib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
alemtuzumab
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
idelalisib + ofatumumab
Sensitive
:
A1